Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.
Holding blue-chip Dow dividend payers in a taxable account quietly hands the IRS a cut of every reinvested dollar, year after year, and the compounding cost over two decades is far steeper…
Both Amgen and Merck write quarterly checks and raise them every year, but only one has the portfolio depth to keep growing that payout through the next brutal round of patent expirations.…
Markets are taking a beating as crude oil surges past $100 and Treasury yields hit multi-year highs, setting up a make-or-break inflation report that could seal the Fed's next move. Wall Street…
Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same…
Wall Street returns from summer vacation to a market suddenly bracing for a rate hike, with fresh analyst calls on Intel, Lockheed Martin, Amgen, and SpaceX adding more pressure points to an…
Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the…
Jim Cramer is flagging an Amgen drug that Wall Street has largely ignored, and he thinks the cardiovascular opportunity behind it could rival the most valuable pharmaceutical market ever created.
One large-cap drugmaker has quietly lapped its peers in 2026 without a single obesity drug in its lineup, while the companies chasing the hottest trend in pharma are fighting for second place…
Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to…
Most dividend investors chase yield and end up watching their payouts shrink or disappear. These five stocks flip that script by pairing decades of uninterrupted payments with the cash flow coverage to…
Generating $86,400 a year in dividends sounds like a number reserved for the ultra-wealthy, but the capital required swings dramatically depending on one variable most investors overlook before they build a single…
Wave Life Sciences has lost nearly 70% of its value this year, yet its RNA platform spans obesity, rare liver disease, and genetic disorders in ways that could make it irresistible to…
Three household names are days away from their ex-dividend dates, and missing the cutoff by even one session means that specific cash payment goes to someone else. The clock is running on…
BioCryst just turned profitable, its HAE drug Orladeyo is minting cash, and a rival's blockbuster acquisition just put the whole rare-disease sector in play. So which pharma giant has the most to…
